Approaching the increasing complexity of non-small cell lung cancer taxonomy

Current Pharmaceutical Design

Volumn 20, Issue 24, 2014, Pages 3973-3981

  Maugeri Saccà, Marcello ^a   Bartucci, Monica ^b   Pagliuca, Alfredo ^b   Patrizii, Michele ^b   Signore, Michele ^b   de Maria, Ruggero ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Cancer stem cells; Loss of function genetic screens; Molecular targeted agents; Non small cell lung cancer; Reverse phase protein arrays

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; TUMOR MARKER;

ARTICLE; CANCER RESEARCH; CANCER STEM CELL; CLINICAL TRIAL (TOPIC); GENE MAPPING; GENETIC DISORDER; GENETIC SCREENING; HUMAN; LOSS OF FUNCTION MUTATION; LUNG NON SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN MICROARRAY; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TAXONOMY; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; GENOTYPE; LUNG NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; GENOTYPE; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; TUMOR MARKERS, BIOLOGICAL;

EID: 84903974371     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113196660759     Document Type: Article

References (94)

1. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008; 359: 1367-1380.
2. Azzoli CG, Baker S Jr, Temin S, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009; 27: 6251-6266.
3. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-3551.
4. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
5. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
6. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361: 958-967.
7. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693-1703.
8. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455: 1069-1075.
9. Cancer Genome Atlas Research Network, Hammerman PS, Hayes DN, Wilkerson MD, et al. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489: 519-525.
10. Sharma SV, Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev 2007; 21: 3214-3231.
11. Ashworth A, Lord CJ, Reis-Filho JS. Genetic interactions in cancer progression and treatment. Cell 2011; 145: 30-38.
12. Tutt A, Robson M, Garber JE, et al. Oral poly(ADPribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376: 235-244.
13. Brough R, Frankum JR, Costa-Cabral S, et al. Searching for synthetic lethality in cancer. Curr Opin Genet Dev 2011; 21: 34-41.
14. Ferrao PT, Bukczynska EP, Johnstone RW, McArthur GA. Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells. Oncogene 2012; 31: 1661-1672.
15. Brooks K, Oakes V, Edwards B, et al. A potent Chk1 inhibitor is selectively cytotoxic in melanomas with high levels of replicative stress. Oncogene 2012 http://dx.doi.org/10.1038/onc.2012.7 [Epub ahead of print].
16. Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012; 483: 100-103.
17. Mullenders J, Bernards R. Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer. Oncogene 2009; 28: 4409-4420.
18. Scholl C, Fröhling S, Dunn IF, et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 2009; 137: 821-834.
19. Babij C, Zhang Y, Kurzeja RJ, et al. STK33 kinase activity is nonessential in KRAS-dependent cancer cells. Cancer Res 2011; 71: 5818-5826.
20. Steckel M, Molina-Arcas M, Weigelt B, et al. Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies. Cell Res 2012; 22: 1227-1245.
21. Whitehurst AW, Bodemann BO, Cardenas J, et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 2007; 446: 815-819.
22. Swanton C, Marani M, Pardo O, et al. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to pacli-taxel and other chemotherapeutic drugs. Cancer Cell 2007; 11: 498-512.
23. Huang S, Hölzel M, Knijnenburg T, et al. MED12 controls the response to multiple cancer drugs through regulation of TGF-P receptor signaling. Cell 2012; 151937-151950.
24. Harris TJ, McCormick F. The molecular pathology of cancer. Nat Rev Clin Oncol 2010; 7: 251-265.
25. Kan Z, Jaiswal BS, Stinson J, et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010; 466: 869-873.
26. Chin L, Gray JW. Translating insights from the cancer genome into clinical practice. Nature 2008; 452: 553-563.
27. van't Veer LJ, Bernards R. Nature. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 2008; 452: 564-570.
28. Ross JS, Hatzis C, Symmans WF, et al. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist 2008; 13: 477-493.
29. Nishizuka S, Charboneau L, Young L, et al. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci USA 2003; 100: 14229-14234.
30. Celis JE, Gromov P. Proteomics in translational cancer research: toward an integrated approach. Cancer Cell; 3: 9-15.
31. Shankavaram UT, Reinhold WC, Nishizuka S, et al. Transcript and protein expression profiles of the NCI-60 cancer cell panel: an in-tegromic microarray study. Mol Cancer Ther 2007; 6: 820-832.
32. Brennan DJ, O'Connor DP, Rexhepaj E, et al. Antibody-based proteomics: fast-tracking molecular diagnostics in oncology. Nat Rev Cancer 2010; 10: 605-617.
33. Sudhir PR, Hsu CL, Wang MJ, et al. Phosphoproteomics identifies oncogenic Ras signaling targets and their involvement in lung ade-nocarcinomas. PLoS One 2011; 6: e20199.
34. Frederick MJ, VanMeter AJ, Gadhikar MA, et al. Phosphoproteo-mic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples. Am J Pathol 2011; 178: 548-571.
35. Mueller C, Liotta LA, Espina V. Reverse phase protein microarrays advance to use in clinical trials. Mol Oncol 2010; 4: 461-481.
36. Voshol H, Ehrat M, Traenkle J, et al. Antibody-based proteomics: analysis of signaling networks using reverse protein arrays. FEBS J 2009; 276: 6871-6879.
37. VanMeter A, Signore M, Pierobon M, et al. Reverse-phase protein microarrays: application to biomarker discovery and translational medicine. Expert Rev Mol Diagn 2007; 7: 625-633.
38. Tibes R, Qiu Y, Lu Y, et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 2006; 5: 2512-2521.
39. Spurrier B, Honkanen P, Holway A, et al. Protein and lysate array technologies in cancer research. Biotechnol Adv 2008; 26: 361-369.
40. VanMeter AJ, Rodriguez AS, Bowman ED, et al. Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type. Mol Cell Proteomics 2008; 7: 1902-1924.
41. Park ES, Rabinovsky R, Carey M, et al. Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Mol Cancer Ther 2010; 9: 257-267.
42. Improta G, Zupa A, Fillmore H, et al. Protein pathway activation mapping of brain metastasis from lung and breast cancers reveals organ type specific drug target activation. J Proteome Res. 2011; 10: 3089-3097.
43. Nanjundan M, Byers LA, Carey MS, et al. Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence. J Thorac Oncol 2010; 5: 1894-1904.
44. He Y, Zhou Z, Hofstetter WL, et al. Aberrant expression of proteins involved in signal transduction and DNA repair pathways in lung cancer and their association with clinical parameters. PLoS One 2012; 7: e31087.
45. Zupa A, Improta G, Silvestri A, et al. A pilot characterization of human lung NSCLC by protein pathway activation mapping. J Thorac Oncol 2012; 7: 1755-1766.
46. Ihle NT, Byers LA, Kim ES, et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst 2012; 104: 228-239.
47. Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell Stem Cell 2012; 10: 717-728.
48. Dieter SM, Ball CR, Hoffmann CM, et al. Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell 2011; 9: 357-365.
49. Vermeulen L, De Sousa E Melo F, van der Heijden M, et al. Wnt activity defines colon cancer stem cells and is regulated by the mi-croenvironment. Nat Cell Biol 2010; 12: 468-476.
50. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988.
51. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
52. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445: 111-115.
53. Todaro M, Iovino F, Eterno V, et al. Tumorigenic and metastatic activity of human thyroid cancer stem cells. Cancer Res 2010; 70: 8874-8885.
54. Eramo A, Lotti F, Sette G, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008 15: 504-514.
55. Eramo A, Haas TL, De Maria R. Lung cancer stem cells: tools and targets to fight lung cancer. Oncogene 2010; 29: 4625-4635.
56. Ho MM, Ng AV, Lam S, Hung JY. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 2007; 67: 4827-4833.
57. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
58. Reynolds SD, Malkinson AM. Clara cell: progenitor for the bron-chiolar epithelium. Int J Biochem Cell Biol 2010; 42: 1-4.
59. Rock JR, Onaitis MW, Rawlins EL, et al. Basal cells as stem cells of the mouse trachea and human airway epithelium. Proc Natl Acad Sci USA. 2009; 106: 12771-12775.
60. Hong KU, Reynolds SD, Watkins S, et al. Basal cells are a mul-tipotent progenitor capable of renewing the bronchial epithelium. Am J Pathol. 2004; 164: 577-588.
61. Liu X, Driskell RR, Engelhardt JF. Stem cells in the lung. Methods Enzymol 2006; 419: 285-321.
62. Xu X, Rock JR, Lu Y, et al. Evidence for type II cells as cells of origin of K-Ras-induced distal lung adenocarcinoma. Proc Natl Acad Sci USA. 2012; 109: 4910-4915.
63. Blenkinsopp WK. Proliferation of respiratory tract epithelium in the rat. Exp Cell Res 1967; 46: 144-154.
64. Rawlins EL. Lung epithelial progenitor cells: lessons from development. Proc Am Thorac Soc. 2008; 5: 675-681.
65. Stripp BR. Hierarchical organization of lung progenitor cells: is there an adult lung tissue stem cell? Proc Am Thorac Soc 2008; 5: 695-698.
66. Hong KU, Reynolds SD, Watkins S, et al. In vivo differentiation potential of tracheal basal cells: evidence for multipotent and unipotent subpopulations. Am J Physiol Lung Cell Mol Physiol 2004; 286: L643-L649.
67. Kim CF, Jackson EL, Woolfenden AE, et al. Identification of bron-chioalveolar stem cells in normal lung and lung cancer. Cell 2005; 121: 823-835.
68. Giangreco A, Arwert EN, Rosewell IR, et al. Stem cells are dispensable for lung homeostasis but restore airways after injury. Proc Natl Acad Sci USA. 2009; 106: 9286-9291.
69. Rawlins EL, Okubo T, Xue Y, et al. The role of Scgb1a1+ Clara cells in the long-term maintenance and repair of lung airway, but not alveolar, epithelium. Cell Stem Cell 2009; 4: 525-534.
70. Berns A. Stem cells for lung cancer? Cell 2005; 121: 811-813.
71. Kim CF. Paving the road for lung stem cell biology: bronchioal-veolar stem cells and other putative distal lung stem cells. Am J Physiol Lung Cell Mol Physiol 2007; 293: L1092-L1098.
72. Maugeri-Saccà M, Vigneri P, De Maria R. Cancer stem cells and chemosensitivity. Clin Cancer Res 2011; 17: 4942-4947.
73. Maugeri-Saccà M, Bartucci M, De Maria R. DNA damage repair pathways in cancer stem cells. Mol Cancer Ther 2012; 11: 1627-1636.
74. Bartucci M, Svensson S, Romania P, et al. Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy. Cell Death Differ 2012; 19: 768-778.
75. Maugeri-Saccà M, Bartucci M, De Maria R. Checkpoint kinase 1 inhibitors for potentiating systemic anticancer therapy. Cancer Treat Rev 2012. doi: pii: S0305-7372(12)00214-9. 10.1016/j.ctrv.2012.10.007. [Epub ahead of print].
76. Dembinski JL, Krauss S. Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma. Clin Exp Metastasis 2009; 26: 611-623.
77. Gao MQ, Choi YP, Kang S, et al. CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene. 2010; 29: 2672-2680.
78. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-715.
79. Levina V, Marrangoni A, Wang T, et al. Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop. Cancer Res 2010; 70: 338-346.
80. Sung JM, Cho HJ, Yi H, et al. Characterization of a stem cell population in lung cancer A549 cells. Biochem Biophys Res Commun 2008; 371: 163-167.
81. Takebe N, Harris PJ, Warren RQ, Ivy SP. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 2011; 8: 97-106.
82. Zhang S, Wang Y, Mao JH, et al. Inhibition of CK2a down-regulates Hedgehog/Gli signaling leading to a reduction of a stemlike side population in human lung cancer cells. PLoS One 2012; 7: e38996.
83. Pallini R, Ricci-Vitiani L, Banna GL, et al. Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res 2008; 14: 8205-8212.
84. Laks DR, Masterman-Smith M, Visnyei K, et al. Neurosphere formation is an independent predictor of clinical outcome in malignant glioma. Stem Cells 2009; 27: 980-987.
85. Liu R, Wang X, Chen GY, et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N. Engl. J. Med 2007; 356: 217-226.
86. Gerger A, Zhang W, Yang D, et al. Common cancer stem cell gene variants predict colon cancer recurrence. Clin. Cancer Res 2011; 17: 6934-6943.
87. Bertolini G, Roz L, Perego P, et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA 2009; 106: 16281-16286.
88. Baiocchi M, Biffoni M, Ricci-Vitiani L, et al. New models for cancer research: human cancer stem cell xenografts. Curr Opin Pharmacol 2010; 10: 380-384.
89. Firestone B. The challenge of selecting the 'right' in vivo oncology pharmacology model. Curr Opin Pharmacol 2010; 10: 391-396.
90. Mordant P, Loriot Y, Lahon B, et al. Bioluminescent orthotopic mouse models of human localized non-small cell lung cancer: feasibility and identification of circulating tumour cells. PLoS One 2011; 6: e26073.
91. Kang Y, Omura M, Suzuki A, et al. Development of an orthotopic transplantation model in nude mice that simulates the clinical features of human lung cancer. Cancer Sci 2006; 97: 996-1001.
92. Kang Y, Omura M, Suzuki A, et al. Proliferation of human lung cancer in an orthotopic transplantation mouse model. Exp Ther Med 2010; 1: 471-475.
93. Burchill SA. What do, can and should we learn from models to evaluate potential anticancer agents? Future Oncol 2006; 2: 201-211.
94. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.